Background & Aims: Elevated serum alanine aminotransferase (ALT) and ␥-glutamyltransferase (GGT) activities are markers of liver injury, but may also be associated with other diseases and death. In a prospective, national, population-based sample, we examined whether elevated ALT and GGT were associated with increased risk of all-cause and disease-specific mortality. In the US population, elevated GGT was associated with mortality from all causes, liver disease, cancer, and diabetes, while ALT was associated only with liver disease mortality.
T he most commonly used marker for chronic liver disease is elevated alanine aminotransferase (ALT) activity. Although produced by other organs, it is found predominantly in hepatocytes and is considered a specific marker for liver injury. Few studies have investigated the relationship of abnormal ALT with mortality. Higher ALT was associated with mortality from all causes in some studies, [1] [2] [3] but not others. 4, 5 Data on mortality from specific causes are even more limited. 1 To our knowledge, the relationship of ALT with mortality outcomes has not been established in the general US population. Elevated ␥-glutamyltransferase (GGT) results from fatty liver disease, both alcoholic and nonalcoholic, cholestatic liver disease, and induction by drugs such as phenytoin. Although detection and diagnosis of liver disease is its primary clinical use, GGT is a nearly ubiquitous epithelial enzyme that is responsible for catabolism of extracellular glutathione. In addition to liver disease, GGT has been associated with high all-cause mortality, cardiovascular disease (CVD) incidence and death, diabetes, and cancer incidence and death. 4,6 -20 Using death certificate data from the third National Health and Nutrition Examination Study (NHANES III), a prospective, population-based sample, we examined whether elevated ALT and GGT were associated with increased mortality overall and from specific causes. The multitude of other variables collected in NHANES III allowed evaluation of potential confounders for mortality. trol and Prevention (CDC). 21 It consisted of interview, examination, and laboratory data collected from a complex multistage, stratified, clustered probability sample of the civilian, noninstitutionalized population aged 2 months and older, with oversampling of the elderly, nonHispanic blacks, and Mexican Americans. The study was approved by the CDC Institutional Review Board, and all participants provided written consent to participate. Of 23,258 sampled persons aged 20 years and older, 16,573 (71%) attended an examination at a mobile examination center. For the primary analyses, we excluded participants with hepatitis B (positive serum hepatitis B surface antigen) or hepatitis C (positive serum hepatitis C antibody) (n ϭ 453). We excluded persons with missing data on hepatitis B or hepatitis C (n ϭ 1047), serum ALT (n ϭ 112), or mortality status (n ϭ 11). The sample for analysis of ALT, therefore, consisted of 14,950 participants. An additional 3320 participants were surveyed before GGT was added to the protocol and, therefore, were excluded from analyses of GGT, resulting in an analysis sample of 11,630. A serum sample was collected and shipped weekly at Ϫ20°C. Serum ALT and GGT concentrations were assayed by using a Hitachi 737 Analyzer (Boehringer-Mannheim Diagnostics, Indianapolis, IN) at the White Sands Research Center, Alamogordo, New Mexico. 22 Abnormal liver enzymes were defined based on recommended cutoffs as a serum concentration of Ͼ30 U/L for men and Ͼ19 U/L for women for ALT, 23 and of Ͼ51 U/L for men and Ͼ33 U/L for women for GGT. 22 Participants were passively followed up for mortality through December 31, 2000, using a probabilistic match that linked NHANES III participants with National Death Index records to ascertain vital status and cause of death This matching methodology is well established and has been described in detail. 24 The accuracy of the NHANES III-National Death Index matching methodology was high in a validation study that applied it to the NHANES I Epidemiologic Follow-up Study (96.1% of decedents and 99.4% of living participants were classified correctly). 25 Persons not matched to a death record were considered to be alive through the end of follow-up and were administratively censored on December 31, 2000. Mortality outcomes were based on death certificate underlying cause of death coded according to the International Classification of Diseases, Ninth Revision (ICD-9) for deaths occurring between 1988 and 1998, and according to the International Classification of Diseases, Tenth Revision (ICD-10) for deaths occurring between 1999 and 2000. 24 Outcomes consisted of all-cause mortality and the following cause-specific mortality: CVD (ICD-9 codes: 410 -414, 428, 429.2, 433-435, 437.0 -437.1, 440, and 444; ICD-10 codes: G45, I20 -I25, I50, I63, I65-I66, I67.2, I67.8, I69.3, I70, and I74), diabetes (ICD-9 code: 250; ICD-10 codes: E10 -E14), liver disease (ICD-9 codes: 70.2-70.9, 275.0 -275.1, and 570 -573; ICD-10 codes: B16 -B19, E83.0 -E83.1, and K70 -K77), neoplasms (ICD-9 codes: 140 -239; ICD-10 codes: C00 -D48), and all other mortality. Deaths with liver cancer coded as underlying cause of death (n ϭ 13) were included with neoplasms.
Data were collected at baseline, as previously described, on factors known or thought to be related to elevated liver enzymes or mortality and included as covariates in multivariate analyses: age (years), sex, ethnicity (non-Hispanic white, non-Hispanic black, Mexican American, other), education (years: Ͻ12, 12, Ͼ12), cigarette smoking (never, former, Ͻ1 pack/day, Ն1 pack/day), alcohol drinking (never, former, Ͻ1 drink/day, 1-2 drinks/day, or Ͼ2 drinks/day), doctor-diagnosed diabetes, physical activity, caffeinated beverage consumption, body mass index (BMI; weight [kg]/height [m 2 ]), waist and hip circumferences, blood pressure, hemoglobin A 1C , serum total and high-density lipoprotein (HDL) cholesterol concentrations, and serum transferrin saturation. 22,26 -32 C-reactive protein was assayed using a Behring Nephalometric Analyzer (Behring Diagnostics Inc, Somerville, NJ) and categorized as 0 -0.3 and Ͼ0.3. 22
Statistical Analysis
Separate analyses were conducted for ALT and GGT. Baseline characteristics were compared by liver enzyme status using a t test for continuous variables or a 2 test for categorical variables. Cumulative mortality during follow-up among persons with and without liver enzyme elevation was calculated using Kaplan-Meier analysis. Hazard rate ratio (HR) estimates (relative risk) for mortality outcomes were calculated by Cox proportional hazard regression analysis (SUDAAN, PROC SURVIVAL, SUDAAN User's Manual, Release 8.0, 2001; Research Triangle Institute, Research Triangle Park, NC) to control for effects of potential risk factors while taking into consideration varying lengths of follow-up. Time at risk was from the date of the NHANES III examination to the date of death or to December 31, 2000. For analyses of cause-specific mortality, participants who died of other causes were censored at the date of death. All factors met the proportional hazard assumption of a relatively constant risk ratio through examination of -log (-log) plots of survival versus time by categories. 33 Multivariate analyses excluded persons with missing values for any risk factor included in the model. A P value of Ͻ.05 was considered to indicate statistical significance. All analyses utilized sample weights that accounted for unequal selection probabilities and nonresponse. All variance calculations accounted for the design effects of the survey using Taylor series linearization. 34 and less physically active, and to have a central fat distribution; higher total cholesterol, diastolic blood pressure, serum transferrin saturation, and prevalence of elevated C-reactive protein; and a lower HDL cholesterol and caffeine intake, but did not differ significantly with respect to sex, systolic blood pressure, alcohol intake, or education ( Table 1) .
The median follow-up among the 14,950 participants was 8.8 years (range, 0.02-12.1 years). The cumulative mortality from all causes was 13.9% (2189 deaths) at 12 years of follow-up. The cause-specific cumulative mortality (underlying cause) was 4.2% (665 deaths) from CVD, 4.2% (499 deaths) from cancer, 0.44% (69 deaths) from diabetes, 0.13% (34 deaths) from liver disease, and 5.5% (922 deaths) from all other causes.
Because persons with elevated ALT were younger (Table 1), they had lower unadjusted cumulative mortality rates for all outcomes except diabetes and liver disease (Table 2) . However, after age-adjustment, an elevated ALT was not associated with a significantly higher risk of all-cause mortality (Table 2) , and this was unchanged after adjusting for multiple factors (Table 2) . For CVD mortality, the HR for persons with an elevated ALT was not increased in either age-adjusted (HR, 0.88; 95% confidence interval [CI] , 0.57-1.4) or multivariate-adjusted analysis (HR, 0.90; 95% CI, 0.56 -1.4). A negative result was likewise found for neoplasms. For diabetes, the cumulative mortality was higher among participants with an elevated ALT ( Table 2) . After adjusting for age, ALT elevation was associated with more than 3 times the risk of diabetes mortality (P ϭ .012) ( Table 2 ). ALT activity was strongly associated with diabetes at baseline. In a model adjusting for multiple factors, but not baseline glucose status, an increased risk remained but no longer reached statistical significance (HR, 2.4; 95% CI, 0.65-9.1) ( Table 2) . Glucose status could not be included in the multivariate-adjusted model because of the relatively small number of diabetes deaths and the strong association of diabetes mortality with abnormal glucose status. However, in a model adjusting for only baseline glucose status, ALT activity was unrelated to diabetes mortality (HR, 0.99; 95% CI, 0.44 -2.2; P ϭ .99). For liver disease, the cumulative mortality was higher among participants with an elevated ALT ( Table 2) . After adjusting for age, ALT elevation was associated with 11 times the risk of liver disease mortality (P Ͻ .001). The risk remained increased more than 8-fold with adjustment for additional factors (P ϭ .003). If liver disease mortality was defined based on any of the multiple causes recorded on the death certificate, rather than underlying cause alone, there were 66 deaths. The cumulative mortality was higher among persons with ALT elevation (0.85%) compared with those without (0.25%). In ageadjusted analysis, persons with elevated ALT had 5 times the risk of liver disease mortality (HR, 5.3; 95% CI, 1.9 -15.3; P ϭ .002), which decreased only slightly in multivariate-adjusted analysis (HR, 4.8; 95% CI, 1.7-13.6; P ϭ .004).
We conducted sensitivity analyses to evaluate the robustness of our findings. (supplementary Tables 1-13, see  supplementary Tables 1-13 online at www.gastrojournal. org.) Because higher alcohol intake is associated with ALT elevation, we excluded 2454 persons who consumed one or more drinks per day. The association of elevated ALT with liver disease mortality was strengthened, while the lack of an association with other mortality outcomes remained unchanged. Secondly, because ALT distributions differ between men and women, we conducted sex-specific analyses. With the exception of an increased risk of diabetes mortality among women but not men in age-adjusted analyses, the results were consistent for men and women separately and jointly. Thirdly, because there is no universally agreed upon definition of abnormal ALT, we ran our analyses using the higher ALT cutoffs of the NHANES III reference laboratory, Ͼ40 U/L for men and Ͼ31 U/L for women, as well as with ALT coded as a continuous and log-transformed variable (because of its skewed distribution). With the higher ALT cut-points, the results were similar except that elevated ALT was not associated with greater diabetes mortality in age-adjusted analysis. However, the number of diabetes deaths among persons with elevated ALT was small. The results were ALT, alanine aminotransferase; CI, confidence interval; CVD, cardiovascular disease. a Estimated using Kaplan-Meier analysis. b Estimated using Cox proportional hazard regression analysis. c Adjusted for age, sex, race-ethnicity, BMI, waist-to-hip ratio, glucose status, total cholesterol, HDL cholesterol, systolic blood pressure, diastolic blood pressure, smoking, alcohol, caffeine, physical activity, C-reactive protein, transferrin saturation, and education. Because of smaller numbers of deaths, Mexican American and other race-ethnicity were combined in models for liver disease and diabetes, education was excluded from the model for liver disease, and glucose status was excluded from the model for diabetes
also similar for log ALT, except for inverse relationships with all-cause and CVD mortality. Fourthly, the 552 participants excluded from the main analysis with viral hepatitis B or C were added back. There was little effect on the results with the exception of an association of elevated ALT with increased all-cause mortality in ageadjusted, but not multivariate-adjusted analysis. Lastly, to address the possible effect of diurnal variation of ALT activity, we adjusted for time of blood draw (AM or PM), and the results were unchanged.
GGT
The prevalence (ϮSE) of elevated GGT was 13.2% (Ϯ0.61%). The relationships of GGT with some participant characteristics differed from those of ALT. Compared with participants with normal GGT, those with elevated GGT were older and more likely to be nonHispanic black, and had fewer years of education and higher systolic blood pressure, but did not differ with regard to HDL level, transferrin saturation, and cigarette smoking. GGT was more strongly associated with caffeine (negatively) and alcohol consumption (positively) than was ALT (Table 1) .
Compared with ALT, elevated GGT was more likely to be related to mortality. For both all-cause mortality and each specific cause, the cumulative mortality was higher among participants with elevated GGT (Table 3) . The risk of all-cause mortality was 60% higher among persons with elevated GGT in age-adjusted analysis, and adjusting for multiple factors had little effect on this relationship. For CVD mortality, the HR for persons with elevated GGT was increased in age-adjusted analysis (HR, 1.5; 95% CI, 1.05-2.0); however, the risk was diminished in multivariate-adjusted analysis and no longer reached statistical significance (HR, 1.3; 95% CI, 0.80 -2.0). Elevated GGT was associated with a 50% higher risk of cancer mortality in both age-adjusted and multivariateadjusted analyses. For diabetes mortality, GGT elevation was associated with almost 5 times the risk in age-adjusted analysis and more than 3 times the risk after adjusting for multiple factors, but not baseline glucose status. Similarly to ALT, GGT activity was strongly associated with diabetes at baseline, and glucose status could not be included in the multivariate-adjusted model because of the small number of diabetes deaths and the strong association of diabetes mortality with abnormal glucose status.
For liver disease mortality, GGT elevation was associated with 19 times the risk (P Ͻ .001) in age-adjusted analysis ( Table 3 ). The risk remained increased 13-fold with adjustment for additional factors (P ϭ .004). If liver c Adjusted for age, sex, race-ethnicity, BMI, waist-to-hip ratio, glucose status, total cholesterol, HDL cholesterol, systolic blood pressure, diastolic blood pressure, smoking, alcohol, caffeine, physical activity, C-reactive protein, transferrin saturation, and education. Because of smaller numbers of liver disease and diabetes deaths, Mexican American and other race-ethnicity were combined in models for these outcomes, glucose status was excluded from the model for diabetes, and covariates included in the model for liver disease were age, sex, race-ethnicity, waist-to-hip ratio, glucose status, smoking, alcohol, caffeine, C-reactive protein, and transferrin saturation
disease mortality was defined based on underlying or other causes of death, rather than underlying cause alone, there were 39 deaths. The cumulative mortality was higher among persons with GGT elevation (1.4%) compared with those without (0.15%). In age-adjusted analysis, persons with elevated GGT had greater than 11 times the risk of liver disease mortality (HR, 11.5; 95% CI, 4.0 -32.8; P Ͻ .001), which was essentially unchanged in multivariate-adjusted analysis (HR, 11.4; 95% CI, 4.0 -33.1; P Ͻ .001).
The same sensitivity analyses were conducted as for ALT. (supplementary Tables 1-13, see supplementary  Tables 1-13 online at www.gastrojournal.org.) After excluding 1821 heavier drinkers, the association with liver disease mortality was strengthened, while other relationships were unchanged. In sex-specific analyses, there were insufficient deaths to evaluate diabetes in men or liver disease in women; HRs for other outcomes were in the same direction for both sexes as in the combined analyses, but no longer reached statistical significance. With log-transformed GGT, the results were similar to the main analysis except that there was no association with cancer. When 419 participants with viral hepatitis B or C were added back, the relationship with liver disease was somewhat attenuated but remained positively associated. With adjustment for time of blood draw (AM or PM), the results were unchanged.
Discussion
For ALT, the key finding of this study was the lack of an association with overall or CVD mortality in a large, national, population-based, prospective study. This was a consistent finding in both age-adjusted and multivariateadjusted analyses. Few studies have performed similar analyses, and their results have been inconsistent and not comparable to those of the current study. A large Korean study found a strong association of all-cause mortality with ALT in men, but not women. It did not exclude persons with chronic viral hepatitis, and digestive disease and cancer mortality constituted a much higher proportion of deaths than in western countries. 1 A similar study from Japan found an association with overall mortality only at low BMI, and there were no exclusions for viral hepatitis. 2 A report that found a higher standardized mortality ratio for raised ALT in Olmsted County, Minnesota, did not exclude persons with known causes of liver disease or control for other mortality risk factors. A notably stronger mortality risk was found at lower levels of ALT for women than for men. 3 In contrast, a study of German male construction workers found a strong association of GGT and aspartate aminotransferase, but not ALT activity, with overall mortality. 4 A Dutch population-based study found a nonstatistically significant increased all-cause mortality risk for participants with the highest third of ALT activity that was attenuated after adjustment for CVD risk factors. 5 Data on the relationship between ALT elevation and CVD mortality are sparse. The Korean study found an association among men but not women. 1 The Dutch study found a higher incidence of fatal and nonfatal coronary heart disease, but not total CVD, among participants in the highest tertile of ALT after controlling for CVD risk factors. 5 An unexpected finding was an inverse relationship with allcause and CVD mortality when ALT was coded as a continuous log-transformed variable. Because of the transformation, this supplemental analysis examined changes in ALT activity mainly within the normal range. The biological significance of these associations is unclear; however, they are outside the primary aim of the study, which was to evaluate whether mortality was increased with an elevated ALT.
The other important finding regarding ALT was its strong association with liver disease mortality, even after excluding participants with chronic viral hepatitis. The relatively small number of liver disease deaths resulted in a wide CI, and the magnitude of the association cannot be determined with certainty. However, the positive direction substantiates a recent American Association for the Study of Liver Disease policy document that supports measuring ALT in the general population as a screening test for liver disease. 35 Given that the increased liver disease mortality was based on a single ALT measurement, this is an especially significant result. It should be noted that the current study was able to detect an association of ALT and mortality from liver disease, but not from CVD, despite fewer than a tenth of the number of deaths from liver disease as from CVD.
Cancer mortality risk was not increased in either ageor multivariate-adjusted analysis. A higher ALT predicted cancer mortality among male Korean workers 1 and in an elderly Italian population. 36 The risk of diabetes mortality was increased among persons with an elevated ALT in age-adjusted analysis, but in multivariate analysis no longer reached statistical significance. Because both ALT activity and diabetes mortality were strongly associated with abnormal baseline glucose status, these results are difficult to interpret. Among prospective studies of ALT elevation and incident diabetes, an association was found in some [37] [38] [39] [40] [41] [42] but not in others. [43] [44] [45] The risk of mortality from all other causes in the current study was slightly and nonstatistically significantly increased in age-and multivariate-adjusted analysis.
GGT is regarded as less specific for liver injury than ALT, and is used less for detection and monitoring of liver disease. However, as a prognostic indicator, it may be as discriminating as ALT for liver disease and more discriminating for other diseases. The increased all-cause mortality found in this study with elevated GGT is supported by a number of studies of disease association and mortality. 8, 13, 46 It is not entirely clear why elevated GGT would be associated with increased mortality. A relationship to oxidative stress is the hypothesis with the most support. [47] [48] [49] Because GGT elevation is associated with heavy alcohol consumption, increased mortality could be a function of heavy drinking. In fact, there was a strong association of elevated GGT with alcohol consumption in the current study (Table 1) . However, both with control for alcohol consumption and with restriction to light and nondrinkers, GGT remained associated with allcause and cause-specific mortality.
There is considerable evidence for increased CVD incidence and mortality with elevated GGT. 7, 12, 14 This association may be independent of such standard risk factors as hypertension and commonly measured blood lipid levels. Active GGT has been experimentally demonstrated in atherosclerotic plaques and may play a role in the development of reactive oxygen species. 50 In multivariate analysis that controlled for numerous CVD risk factors, we did not find a statistically significant relationship of elevated GGT to CVD mortality, although the HR of 1.3 did indicate an increased risk.
Numerous studies have demonstrated an association of GGT activity with diabetes in both cross-sectional and longitudinal studies. 6,9,10,15,51-53 The strong association of GGT and insulin resistance may be the main reason for this association. There is less evidence for an association of GGT with cancer incidence and mortality. An Austrian population-based study found a clear dose-response relationship of GGT with cancer incidence. 18, 19 Both men and women had an increased risk of malignant neoplasms of the digestive organs and respiratory system/intrathoracic organs. A hospital-based cohort study, also from Austria, found an association of GGT with increased cancer mortality. 8 In addition to the aforementioned relationship of GGT to oxidative stress as a potential explanation for the association with cancer, expression of GGT in cancer cells has been associated with chemotherapeutic drug resistance. 54 Finally, the current study confirmed the well-known relationship of GGT to liver injury by demonstrating a mortality risk at least as great as for elevated ALT, even with adjustment for several known liver disease risk factors. GGT has been strongly associated with both alcoholic and nonalcoholic fatty liver disease. [55] [56] [57] [58] [59] There is surprisingly less evidence for elevated GGT and liver disease outcomes, including mortality. 8, 60 We found a high relative risk of liver disease mortality with elevated GGT that was not strongly influenced by BMI and alcohol consumption. Although this result suggests that GGT could be considered a prognostic marker for liver disease, the increased risk was based on relatively few deaths and requires confirmation.
As previously reported, limitations of using NHANES to study liver injury are that liver biopsies cannot be conducted on the general population and ultrasound imaging was not performed, so single serum liver enzyme levels must be relied on as markers for liver injury. 26 -28 In addition, there was a possible loss of ALT activity after the brief storage and the shipping that were used in NHANES III. However, the stability of serum ALT was concluded by a review to be adequate for shipping and storage if low temperatures were maintained. 61 Degradation of ALT activity could have diminished an association of ALT with mortality. Given the strong association of elevated ALT with mortality from liver disease, we believe that any effect would have been small. Because most ALT elevations were modest, we were unable to examine the relationship of higher abnormal levels with mortality. Another limitation of the current study is the lack of validation of cause of death. Although ascertainment of vital status using the National Death Index is very high, assigning cause of death based on death certificate diagnoses may lead to misclassification. Such inaccuracies might have resulted in misclassification of some participants, but they should not have led to biased results. The fact that all-cause mortality and certain cause-specific mortality were increased for high GGT argues against a strong effect for misclassification for common causes of death. Finally, the number of mortality outcomes, especially for liver disease and diabetes, was limited by the 12-year duration of follow-up. These limitations are balanced by the benefits of a large, national, populationbased sample, particularly the avoidance of ascertainment bias that occurs in clinical studies of selected patients and the ability to generalize the results to the US population. In conclusion, in the US population, elevated GGT was associated with mortality from all causes, liver disease, cancer, and diabetes, while ALT was associated only with liver disease mortality. ALT, alanine aminotransferase; CI, confidence interval; CVD, cardiovascular disease. a Estimated using Kaplan-Meier analysis. b Estimated using Cox proportional hazard regression analysis. c Adjusted for age, race-ethnicity, body mass index, waist-to-hip ratio, glucose status, total cholesterol, high-density lipoprotein cholesterol, systolic blood pressure, diastolic blood pressure, smoking, alcohol, caffeine, physical activity, C-reactive protein, transferrin saturation, and education. Because of smaller numbers of deaths, Mexican American and other race-ethnicity were combined in models for liver disease and diabetes, alcohol drinking was excluded from the model for liver disease, and glucose status and alcohol drinking were excluded from the model for diabetes ALT, alanine aminotransferase; CI, confidence interval; CVD, cardiovascular disease. a Estimated using Kaplan-Meier analysis. b Estimated using Cox proportional hazard regression analysis. c Adjusted for age, sex, race-ethnicity, body mass index, waist-to-hip ratio, glucose status, total cholesterol, high-density lipoprotein cholesterol, systolic blood pressure, diastolic blood pressure, smoking, alcohol, caffeine, physical activity, C-reactive protein, transferrin saturation, and education. Because of smaller numbers of deaths, Mexican American and other race-ethnicity were combined in the model for liver disease, and glucose status was excluded from the model for diabetes
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Supplementary CI, confidence interval; CVD, cardiovascular disease; GGT, ␥-glutamyltransferase; HR, hazard ratio. a Estimated using Cox proportional hazard regression analysis. b Adjusted for age, sex, race-ethnicity, body mass index, waist-to-hip ratio, glucose status, total cholesterol, high-density lipoprotein cholesterol, systolic blood pressure, diastolic blood pressure, smoking, alcohol, caffeine, physical activity, C-reactive protein, transferrin saturation, education, and time of blood draw. Because of smaller numbers of liver disease and diabetes deaths, Mexican American and other race-ethnicity were combined in models for these outcomes, glucose status was excluded from the model for diabetes, and covariates included in the model for liver disease were age, sex, race-ethnicity, waist-to-hip ratio, glucose status, smoking, alcohol, caffeine, C-reactive protein, and transferrin saturation. c GGT Ͼ51 U/L in men or Ͼ33 U/L in women.
Supplementary CI, confidence interval; CVD, cardiovascular disease; GGT, ␥-glutamyltransferase; HR, hazard ratio. a Estimated using Cox proportional hazard regression analysis. b Adjusted for age, sex, race-ethnicity, body mass index, waist-to-hip ratio, glucose status, total cholesterol, high-density lipoprotein cholesterol, systolic blood pressure, diastolic blood pressure, smoking, alcohol, caffeine, physical activity, C-reactive protein, transferrin saturation, education, and time of blood draw. Because of smaller numbers of liver disease and diabetes deaths, Mexican American and other race-ethnicity were combined in models for these outcomes, glucose status was excluded from the model for diabetes, and covariates included in the model for liver disease were age, sex, race-ethnicity, waist-to-hip ratio, glucose status, smoking, alcohol, caffeine, C-reactive protein, and transferrin saturation.
